Literature DB >> 15261563

Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire.

O R Hommes1, H L Weiner.   

Abstract

Immunosuppressive treatment is a current practice in MS therapy. Mitoxantrone has gained largest acceptance. Differences in clinical indications of mitoxantrone, cyclophosphamide, azathioprine and methotrexate are described. Copyright 2004 Elsevier B.V.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15261563     DOI： 10.1016/j.jns.2004.04.022

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


  6 in total

Review 1.  Cyclophosphamide for multiple sclerosis.

Authors:  L La Mantia; C Milanese; N Mascoli; R D'Amico; B Weinstock-Guttman
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study.

Authors:  Paola Perini; Massimiliano Calabrese; Michela Tiberio; Federica Ranzato; Leontino Battistin; Paolo Gallo
Journal:  J Neurol       Date:  2006-04-11       Impact factor: 4.849

Review 3.  Azathioprine for multiple sclerosis.

Authors:  I Casetta; G Iuliano; G Filippini
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

4.  New insights into neuromyelitis optica.

Authors:  Woojun Kim; Su-Hyun Kim; Ho Jin Kim
Journal:  J Clin Neurol       Date:  2011-09-29       Impact factor: 3.077

Review 5.  Azathioprine. Safety profile in multiple sclerosis patients.

Authors:  L La Mantia; N Mascoli; C Milanese
Journal:  Neurol Sci       Date:  2007-12       Impact factor: 3.830

6.  The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.

Authors:  Emanuele D'Amico; Carmela Leone; Giusi Graziano; Maria Pia Amato; Roberto Bergamaschi; Paola Cavalla; Gabriella Coniglio; Giancarlo Di Battista; Maria Teresa Ferrò; Franco Granella; Enrico Granieri; Alessandra Lugaresi; Giacomo Lus; Enrico Millefiorini; Carlo Pozzilli; Gioacchino Tedeschi; Mario Zappia; Giancarlo Comi; Maria Trojano; Vito Lepore; Francesco Patti
Journal:  PLoS One       Date:  2016-06-27       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.